Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 5
Submit an article Journal homepage
292
Views
10
CrossRef citations to date
0
Altmetric
Original Article

INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse – a Swedish real life experience

Castedal MariaThe Transplant Institute, Sahlgrenska University Hospital, Institution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Segenmark MichaelDepartment of Medicine, Division of Infectious Diseases, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Cederberg SusanneDepartment of Medicine, Division of Infectious Diseases, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
,
Skoglund CatarinaThe Transplant Institute, Sahlgrenska University Hospital, Institution of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
&
Weiland OlaDepartment of Medicine, Division of Infectious Diseases, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, SwedenCorrespondence[email protected]
Pages 585-588 | Received 23 Nov 2016, Accepted 11 Jan 2017, Published online: 13 Feb 2017

References

  • Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012;57:675–688.
  • Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192–1204.
  • Gjertsen H, Weiland O, Oksanen A, et al. Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplant Proc. 2006;38:2675–2676.
  • Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–836.
  • Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896.
  • Melum E, Friman S, Bjoro K, et al. Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma. J Hepatol. 2007;47:777–783.
  • Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
  • Charlton M, Gane E, Manns M, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology. 2013;58(Suppl. 1):LB–2.
  • Cheung MC, Walker AJ, Hudson BE, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;65:741–747.
  • Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64:1224–1231.
  • Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–1505.
  • Welzel T, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016. pii: gutjnl-2016-312444. doi: 10.1136/gutjnl-2016-312444. [Epub ahead of print].
  • Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transpl. 2013;13:1601–1605.
  • Zeuzem S, Hezode C, Bronowicki JP, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol. 2016;64:292–300.
  • Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–1417.
  • Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847.
  • Fontana RJ, Brown RS Jr, Moreno-Zamora A, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016;22:446–458.
  • Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360–369.
  • Everson GT. Waiting for “The Liver” - no longer? J Hepatol. 2016;65:467–469.
  • Ackefors M, Castedal M, Dahlgard O, et al. Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation. J Infect Dis. 2015;47:209–217. PubMed PMID: 25650729.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.